Skip to main content
logo
Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
7.67
+0.63 (8.95%)
Aug 12, 2026, 4:00 PM EDT - Market closed

Entrada Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
4.6925.42210.78129.01--
Revenue Growth
-94.10%-87.94%63.38%---
Gross Profit
4.6925.42210.78129.01--
Selling, General & Admin
40.4741.0538.4732.2930.6415.2
Research & Development
140.74142.27125.3199.8866.6135.93
Total Operating Expenses
181.21183.32163.77132.1897.2551.13
Operating Income
-176.53-157.947.01-3.16-97.25-51.13
Interest Income
11.5715.0719.4715.222.63-0.03
Total Non-Operating Income (Expense)
11.5715.0719.4715.222.63-0.03
Pretax Income
-164.96-142.8366.4912.06-94.62-51.16
Provision for Income Taxes
0.820.920.86-18.74--
Net Income
-165.78-143.7565.6330.8-94.62-51.16
Net Income to Common
-165.78-143.7565.63-6.69-94.62-51.16
Net Income Growth
------
Shares Outstanding (Basic)
42413733316
Shares Outstanding (Diluted)
42413933316
Shares Change
0.62%6.07%18.01%5.62%399.27%467.09%
EPS (Basic)
-3.96-3.471.76-0.20-3.02-8.16
EPS (Diluted)
-3.96-3.471.68-0.20-3.02-8.16
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-134.35-129.55-44.72134.19-96.67-55.44
Free Cash Flow Growth
------
Free Cash Flow Per Share
-3.22-3.13-1.154.06-3.09-8.85
Gross Margin
100.00%100.00%100.00%100.00%--
Operating Margin
-3767.07%-621.13%22.30%-2.45%--
Profit Margin
-3537.73%-565.48%31.13%23.87%--
FCF Margin
-2867.07%-509.63%-21.21%104.01%--
EBITDA
-172.76-153.850.78-0.32-95.35-50.01
EBITDA Margin
-3686.79%-605.02%24.09%-0.25%--
EBIT
-176.53-157.947.01-3.16-97.25-51.13
EBIT Margin
-3767.07%-621.13%22.30%-2.45%--
Effective Tax Rate
-0.50%-0.65%1.29%-155.45%0.00%0.00%
SEC Filings: 10-K · 10-Q